Navigation Links
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease
Date:7/15/2009

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety.

The announcement came at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria where EnVivo presented its findings. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognitive dysfunction associated with Alzheimer's disease and schizophrenia.

"EVP-6124 appears to be safe and was well tolerated over a month of dosing," commented Kees Been, CEO of EnVivo. "Most excitingly, the cognition improvement was observed on top of the effect of acetylcholinesterase inhibitors the patients were already taking. This is a strong indicator of a biologic and potentially useful clinical effect."

In this Phase Ib/IIa safety and biomarker study in patients with mild to moderate Alzheimer's disease already taking chronic acetylcholinesterase inhibitor (AChEI) therapy (donepezil or rivastigmine), three separate doses of EVP-6124 or a placebo dose were administered to a total of 48 subjects for 28 days. Safety and tolerability were determined by adverse events, clinical assessments, and laboratory studies. Cognition in AD patients was measured using the computerized CogState battery system and a group of traditional 'paper and pencil' cognition tests.

Minimal treatment-emergent adverse effects were observed during the trial and there were no serious adverse events. Improvement in a number of cognition measures in EVP-6124 treated patients were observed compared to placebo treated patients. These included measures of attention, verbal and language fluency,
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. EnVivo Pharmaceuticals Announces Executive Appointment
2. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...4-year veteran of the high-technology industry, ha...development and intellectual property management c...e. The company also plans to invest in promising .... , Monterey, CA (PRWEB) ...veteran of the high-technology industry, has forme...
(Date:11/30/2009)...wire/ -- Acuo Technologies, developers of high-per...igration tools and services, today announced contr... Vendor Neutral Archive (VNA), providing the found...f hospitals, clinics and affiliates. ,, The arc...DICOM Services Grid(TM) Software. The Acuo VNA ar...
(Date:11/30/2009)...wire/ -- Biopharmaceutical company Kiadis,Pharma a...nrolled in its,multinational registration clinical...w reduction in transplant related mortality (TRM) ...ransplantation with a mismatched,(haplo-identical)...logeneic,stem cell transplantation but without hav...
(Date:11/30/2009)...FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq...dministration (FDA) has granted orphan drug design...dine phosphate, for the rare autoimmune disease La...as previously received orphan drug designation in ... Medicinal Products for Human Use of the European ...
Breaking Biology Technology:Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
...omated the steps for the processing, storage and c...he New York Blood Center,s National Cord Blood P...stem, developed by ThermoGenesis Corp . and distr...harvesting of the stem cell-rich cord blood into a...ml, and in a functionally closed and sterile syste...
...tors alone, you might conclude its a real-life ver... in the hit animated movie Cars. But just as Radia...e theres a more prosperous, real-life road ahead f...use without a healthy Milwaukee, most of Wisconsin...ics confirms what most observers suspected: Milwau...
... medical informatics technology, announced that it...tion manager at the community health organization ... March 2006 and, according to ThedaCare, it has be... Evercore system integrates all of the clinical ob...nd, and makes the images of those devices visible ...
Other Biology Technology:GE partners with New York blood center 2It's an economic fact: As Milwaukee goes, so goes Wisconsin 2It's an economic fact: As Milwaukee goes, so goes Wisconsin 3
(Date:11/30/2009)... A team of scientists from The Forsyth Institute, ...DC and the Wadsworth Center, have used state-of-th...ecture of Treponema pallidum, the bacterium which ...tructure of the bacteria can now be shown in three... the pathogen and reveals previously unknown featu...
(Date:11/30/2009)... HOUSTON (Nov. 30, 2009) Scientists and engineers...cine and energy will come together Dec. 7 with le...ing oil and pumping blood. , Much like moving oi...rough the body. Both systems need clean, well-fun...es or corrosion, to function efficiently. Both ind...
(Date:11/30/2009)... As global temperatures continue to rise scientist...rstanding how species respond and adapt. In a pape..., Dr Francisco Rodriguez-Trelles and Dr Miguel Rod...y global warming of approximately 0.6˚C has a...r challenge facing ecologists and evolutionary bio...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3How can scientists measure evolutionary responses to climate change? 2New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 1New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 2New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 3New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 4New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 58329 5Engineers produce how to guide for controlling the structure of nanoparticles 14270 1Engineers produce how to guide for controlling the structure of nanoparticles 14270 2Surgery Best for Carpal Tunnel Syndrome 58324 1Surgery Best for Carpal Tunnel Syndrome 58324 2Surgery Best for Carpal Tunnel Syndrome 58324 3
... 2008) -- On Nov. 8 and 9, Morgan Stanley Children...niversity Medical Center will host an "Innovations...att New York, which will feature lectures by inter...al research, genetic findings and stem cell therap... about congenital and primary immunodeficiencies; ...
...tudy led by investigators from Massachusetts Gener...look at how interactions between genes underlie a ...ory. Functional imaging studies reveal how a comb...ted with reduced activity of important brain struc...controls. The report has been released online in ...
...th expert Daniel Hayes, Ph.D., of the New York Cit... that a form of vitamin D could be one of our body... of radiation. Writing in the International Journ...ol, the active form of vitamin D, may protect us f...fe protective agent before or after a low-level nu...
Other Biology News:Innovations in Pediatric Medicine International Conference brings together pediatrics experts 2Interaction between gene variants may alter brain function in schizophrenia 2Could vitamin D save us from radiation? 2
Goat Anti-Ephrin B2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-LAP1 Monoclonal Antibody, Unconjugated, Clone RL13 from Abcam
Sheep Anti-Pig Malate Dehydrogenase Polyclonal Antibody, Unconjugated from Abcam
TaqMan Rodent GAPDH Control Reagents from Applied Biosystems
Biology Products: